Strategic collaboration combines KYBORA’s global biopharma network with ACA Pharma’s 30–90 day Macau registration model to expedite access for rare disease and pediatric therapies in China. KYBORA and ACA Pharma…
Redefining Treatments for Neurodegenerative Diseases Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and Huntington’s disease affect millions…
Trends, Insights, and Strategic Implications The biopharma industry in 2024 experienced a transformative year marked by high-value mergers and acquisitions…
Executive Summary – The U.S. Food and Drug Administration (FDA)’s December 2024 guidance,“Expedited Program for Serious Conditions – Accelerated Approval…
Executive Summary – The FDA’s Accelerated Approval (AA) pathway has been instrumental inexpediting treatments for serious conditions, but recent scrutiny,…
KYBORA, a leading global advisory firm specializing in biopharma transactions, served as the exclusiveadvisor to Xbrane Biopharma AB (Nasdaq Stockholm:…
